La pratique clinique de la médecine nécessite la reconnaissance de la maladie dont souffre le patient par le médecin. Pour cela, celui-ci rationnalise les signes permettant d’isoler une entité réaliste et de la classer dans la nosologie de référence. Contrairement à d’autres pratiques, le modèle biomédical utilise la méthodologie scientifique du recensement, dans une logique de classification pour définir les maladies. Du fait de son processus de simplification, ce modèle néglige les cas de transition ou les cas complexes. En rhumatologie, ce raisonnement classifiant est mis à l’épreuve par le manque d’objectivité et de spécificité des éléments sur lesquels s’appuie le clinicien pour construire le diagnostic, mais aussi par la complexité des mécanismes physiopathologiques des maladies rhumatismales. Ces maladies peuvent en effet se confondre ou s’intriquer, pour aboutir alors à la description de nouvelles entités non envisagées dans les classifications. Nous présentons dans cette revue les difficultés rencontrées au cours de l’exercice de la médecine dans ces contextes, et comment, à partir d’un cas concret, vécu, celles-ci peuvent donner naissance à la proposition d’un nouveau taxon1.
This review examines the concept of “psout”, an overlap syndrome of hyperuricemic psoriatic arthritis (HU-PsA) and co-existing gout and PsA. The manuscript explores its epidemiology, pathophysiology, clinical implications, and treatment strategies, focusing on emerging data since its first description in 2020. The psout concept is sustained by shared inflammatory and metabolic pathways between gout and PsA, contributing to a broad spectrum of phenotypes and moderate-to-severe clinical manifestations. Monosodium urate crystals and hyperuricemia are central to this overlap, influencing cytokine production, keratinocyte activation, and immune responses, being able to activate both innate and acquired immunity. Clinical management is complex due to diagnostic challenges and therapeutic considerations not yet implemented in international recommendations. Emerging data from clinical trials underscore the significance of hyperuricemia in worsening PsA outcomes while highlighting the potential of personalized treatments. Future research into shared pathophysiological mechanisms, the accurate description of the diversity of phenotypes, innovative imaging assessments, and therapeutic strategies could provide insights into the interplay of these two conditions and enhance patient outcomes.
The immune microenvironment of classical Hodgkin lymphoma (cHL) is characterized by rare Hodgkin and Reed–Sternberg (HRS) cells surrounded by dysfunctional lymphocytes. HRS cells exploit the PD-L1–PD-1 axis to suppress antitumor immunity. Although PD-1 blockade is effective in some patients with relapsed cHL, the mechanisms of resistance remain unclear. We investigated T-cell dynamics in cHL using whole-exome sequencing (WES) of plasma ctDNA and longitudinal single-cell RNA and T-cell receptor sequencing of peripheral blood lymphocytes from a relapsed patient before and after anti–PD-1 therapy. Findings were validated by flow cytometry in 11 patients with relapsed cHL (pre– and post–anti-PD-1) and 6 healthy age-matched controls, and by PhenoCycler imaging of 18 tissue biopsies (13 diagnostic and 5 post–anti-PD-1). WES identified two somatic mutations at relapse—MEX3B-Lys201* and TNFRSF10A-Tyr409His—potentially contributing to immune escape. Immune profiling revealed clonal expansion of CD8+ T cells at relapse and a shift from precursor-like (TCF1+) to intermediately exhausted (CX3CR1+) phenotypes. This pattern was confirmed in other patients with relapsed cHL, in whom TCF1+ populations diminished, and CX3CR1+ T-bet+ populations became dominant among those progressing on anti–PD-1 therapy. In post–anti-PD-1 treatment tissue biopsies, CD8+ T cells exhibited increased levels of exhaustion markers (TCF1− and CX3CR1+), a phenotype not observed in diagnostic cHL or healthy donors. These results suggest that durable anti–PD-1 responses depend on the preservation of progenitor exhausted T cells, whereas relapse after anti–PD-1 is marked by the accumulation of intermediately exhausted clones. Strategies to prevent T-cell exhaustion or combine anti–PD-1 with approaches targeting antigen burden may help overcome resistance.